Latest Zymeworks News & Updates

See the latest news and media coverage for Zymeworks. We track all announcements, press releases, and industry mentions in real time, all in one place.

Zymeworks

Biotechnology company developing medicines for difficult-to-treat diseases

zymeworks.com

Headquarters: Vancouver, Canada
Founded year: 2003
Company type: Public company
Number of employees: 250–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Zymeworks

In short: Zymeworks completed its $929 million acquisition of Theravance Biopharma and secured FDA approval for its cancer treatment, zanidatamab.

Company announcements

September 23 Zymeworks

Zymeworks closes Theravance merger and raises $350M

Theravance becomes a subsidiary while CVRs are issued to shareholders. Senior secured notes with an 8.25% interest rate mature in 2036.

September 23 Zymeworks

Zymeworks filed an 8-K report on Sep 23 2026

The filing covers unscheduled material events or corporate actions for Zymeworks Inc as a current report.

August 31 Zymeworks

Zymeworks partners announce positive phase three survival results

The data highlights improved clinical outcomes for patients with HER2-positive advanced gastric tumors, advancing targeted treatment options.

August 25 Zymeworks

Zymeworks earns $250 million milestone

Partner Jazz Pharmaceuticals received FDA approval for Ziihera regimens in HER2+ gastroesophageal adenocarcinoma.

Media coverage

September 28 The Globe and Mail

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - The Globe and Mail

Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI ® expected...

September 23 Zone Bourse

Theravance Biopharma, Inc. announces the resignation of Rick E Winningham from his position as Chief Executive Officer, effective September 23, 2026

Theravance Biopharma, Inc. stated that, as part of the closing of the merger and as provided for in the merger agreement, on the date...

September 19 The Globe and Mail

Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed...

September 10 Seeking Alpha

Theravance faces lawsuits to block Zymeworks acquisition

Three legal actions challenge the $929M deal over alleged undisclosed material information and shareholder proxy issues.

Never miss news about Zymeworks

Track Zymeworks and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Zymeworks competitors & trending companies

Browse news for competitors to Zymeworks and other trending companies.